Jefferies analyst Lucy Codrington has maintained their bullish stance on GALD stock, giving a Buy rating on July 8.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lucy Codrington’s rating is based on the strong growth prospects of Galderma Group AG, particularly driven by the performance of Nemluvio in the US market. The company’s expected net sales growth of 12.8% for 2025 surpasses the management’s target range, indicating a robust outlook. This optimistic forecast is supported by the increasing demand for Nemluvio, which is anticipated to counterbalance weaker expectations outside the US.
Moreover, the market feedback suggests that investors are already expecting Nemluvio’s performance to exceed consensus estimates, further reinforcing the positive sentiment. Despite some concerns about the slowing growth of Cetaphil in the US, the overall growth dynamics and potential for upward adjustments in sales targets make Galderma Group AG an attractive investment opportunity.
According to TipRanks, Codrington is an analyst with an average return of -4.8% and a 39.29% success rate.
In another report released on July 8, Barclays also initiated coverage with a Buy rating on the stock with a CHF133.00 price target.